Sildenafil Tablet, Film Coated
Product Images NDC 82647-211

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 82647-211). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Reyoung Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg-1000s.jpg (100mg 1000s)

Label for Sildenafil Tablets, USP 100 mg film-coated tablets by Reyoung Corporation. The label displays the product name, strength 100 mg, quantity of 1000 tablets, Rx only, storage instructions, and a barcode. The product is distributed by Reyoung Corporation in Gaithersburg, MD.*

FDA Label Image

100mg-30s.jpg (100mg 30s)

Sildenafil Tablets, USP 100 mg film-coated oral tablets in a carton. The label indicates 30 tablets per package with Rx only designation. Manufactured or distributed by Reyoung Corporation, Gaithersburg, MD. The label includes storage instructions and mentions dosage and usage information are provided separately.*

FDA Label Image

25mg-1000s.jpg (25mg 1000s)

Label for Sildenafil Tablets, USP, 25 mg film-coated oral tablets. The label indicates a package size of 1000 tablets and is marked Rx Only. The product is labeled by Reyoung Corporation with storage instructions and a barcode present.*

FDA Label Image

25mg-30s.jpg (25mg 30s)

Sildenafil Tablets USP 25 mg film-coated oral tablets packaging label by Reyoung Corporation. The label indicates a package of 30 tablets, Rx only, with storage instructions and dosage information. It includes the NDC number 82647-210-30 and a barcode.*

FDA Label Image

50mg-1000s.jpg (50mg 1000s)

Sildenafil Tablets USP 50 mg film-coated oral tablets with a package size of 1000 tablets. The label shows storage instructions and dosage information, indicating the product is distributed by Reyoung Corporation, Gaithersburg, MD. The label includes the NDC number 82647-211-14 and a barcode.*

FDA Label Image

50mg-30s.jpg (50mg 30s)

Sildenafil Tablets, USP 50 mg film-coated tablets in a package of 30, labeled for prescription use only. The label includes storage instructions, dosage and usage information, and the distributor Reyoung Corporation. Also visible is the NDC code 82647-211-30 and a barcode.*

FDA Label Image

Figure1.jpg (Figure1)

A line graph illustrating the mean change from baseline in sitting systolic blood pressure over 24 hours for healthy volunteers. The x-axis shows time post-dose in hours, and the y-axis shows systolic blood pressure change in mmHg. Two lines compare Sildenafil 100 mg and placebo effects over time.*

FDA Label Image

Figure2.jpg (Figure2)

A line graph depicting the mean standing systolic blood pressure change from baseline over time postdose in hours. Two data sets are shown: one for Doxazosin versus Placebo and another for Doxazosin versus Sildenafil 25 mg. The y-axis represents the change in blood pressure in mmHg, and the x-axis represents time in hours postdose.*

FDA Label Image

Figure3.jpg (Figure3)

A line graph titled 'Mean Standing Systolic Blood Pressure Change from Baseline,' showing time postdose in hours on the x-axis and change in systolic blood pressure in mmHg on the y-axis. Two data sets compare Doxazosin plus Placebo versus Doxazosin plus Sildenafil 50 mg over an 8-hour period.*

FDA Label Image

Figure4.jpg (Figure4)

A line graph depicting mean standing systolic blood pressure change from baseline over time after dosing, comparing doxazosin combined with sildenafil 100 mg versus doxazosin with placebo. The x-axis shows time in hours post-dosing (0 to 8 hours) and the y-axis represents blood pressure change in mmHg.*

FDA Label Image

Figure5.jpg (Figure5)

A line graph depicting mean plasma concentrations of Sildenafil over time in healthy male volunteers after a commercial tablet dose. The x-axis represents time post dose in hours up to 24 hours, and the y-axis shows plasma concentration in ng/mL, peaking shortly after dosing and declining thereafter.*

FDA Label Image

Figure6.jpg (Figure6)

Two bar graphs comparing the effect of Sildenafil and Placebo on maintenance of erection by baseline score. The vertical axis shows percentage of patients at endpoint, and the horizontal axis shows baseline scores ranging from 0 to 5. Different shades represent various response categories as indicated by the legend on the right.*

FDA Label Image

Figure7.jpg (Figure7)

A bar chart titled 'Figure 7. Percentage of Patients Reporting an Improvement in Erections' comparing four treatment groups: Placebo, Sildenafil 25 mg, Sildenafil 50 mg, and Sildenafil 100 mg. The vertical axis shows the percentage of patients reporting improvement, with values increasing from left to right. The percentages are 24% for placebo, 63% for Sildenafil 25 mg, 74% for Sildenafil 50 mg, and 82% for Sildenafil 100 mg. The chart includes patient sample sizes for each group and notes an overall treatment p-value of less than 0.0001.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure diagram of sildenafil, showing the molecular arrangement as part of the FDA-approved drug product labeling by Reyoung Corporation for sildenafil tablets.*

FDA Label Image

Table-2.jpg (Table 2)

Table displaying adverse reactions reported by 2% or more of patients treated with Sildenafil and more frequent than placebo during flexible-dose Phase II/III studies. The table compares the percentage of patients experiencing headache, flushing, dyspepsia, nasal congestion, abnormal vision, back pain, dizziness, and rash between Sildenafil and placebo groups.*

FDA Label Image

Tablet-3 (Table 3)

A data table titled 'Hemodynamic Data in Patients with Stable Ischemic Heart Disease after Intravenous Administration of 40 mg of Sildenafil.' It presents mean values with standard deviations for various cardiovascular parameters including PAOP, Mean PAP, Mean RAP, Systolic and Diastolic SAP, cardiac output, and heart rate measured at rest and after 4 minutes of exercise, comparing baseline values and values after sildenafil administration.*

FDA Label Image

Table1.jpg (Table1)

A data table listing adverse reactions reported by at least 2% of patients treated with Sildenafil at doses of 25 mg, 50 mg, and 100 mg compared to placebo. Reactions include headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash with corresponding percentages for each dose group and placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.